MKI67 and neoplasm: TLS prophylaxis should be considered for patients with high tumor burden (SPD ≥ 100 cm2 or bulky mass with diameter ≥ 10 cm) or high tumor proliferation activity (Ki67 ≥ 85%)101,102.